Biogen Added To Alteogen’s Long List Of Partners
Following a deal with Tesaro in January, Alteogen inks another global out-licensing agreement for its subcutaneous delivery enabling platform technology, this time with Biogen.
Scrip - March 26, 2026

GE HealthCare’s Photonova Spectra FDA Clearance Heats Up PCCT Race With Siemens
GE HealthCare has spent $5.1bn and decades developing its answer to Siemens Healthineers' photon-counting CT dominance. The FDA just cleared it. Now the harder question – whether the Photonova Spectra's Deep Silicon technology can convert claims into market share – begins.
Medtech Insight - March 25, 2026

Medtronic Expands OmniaSecure Approval to Left Bundle Branch Pacing, Raising Competitive Stakes
A new FDA indication for Medtronic’s OmniaSecure defibrillation lead marks a step forward for conduction-system pacing, enabling defibrillator-equipped systems to target a portion of the heart known as the left bundle branch area.
Medtech Insight - March 25, 2026

Thorne’s Picture Of Dietary Supplement Personalization: ‘Meet Them On Their Journey’
“What they want when they think about personalization, is that you meet them on their journey, where they are on their terms. That's what personalization is. How do brands do that? You can't do that by just broadcasting an ad,” CEO Colin Watts says.
HBW Insight - March 26, 2026

GDUFA IV: Industry Questions Proposed Four-Month pOAI Goal Extension
Sponsors thought a shorter goal date extension was appropriate if a facility received the unofficial potential Official Action Indicated tag, but the FDA said it needs the extra time to complete the final steps in the application review.
Generics Bulletin - March 25, 2026

IGBA Picks Gaunt As New Secretary General
The IGBA has named former Medicines for Europe, Novartis and Sandoz executive Ana Gaunt as the new secretary general of the global generics and biosimilars industry association.
Generics Bulletin - March 25, 2026

‘More Can Be Done’ – AAM’s Keeton On Reshaping The US Biosimilars Market
Despite recent wins on streamlining and interchangeability, the US biosimilars industry continues to face challenges such as IRA price negotiation, dysfunctional pricing dynamics and PBM distortions, says AAM Biosimilars Council chief Alex Keeton.
Generics Bulletin - March 25, 2026

Celltrion Ramps Capacity To Power Global Biosimilars Expansion
Celltrion will invest KRW1.23trn in two new Songdo plants, adding 180,000L of capacity as part of a broader Korea-US expansion that will lift global drug-substance capacity to 571,000L and support pipeline growth and CMO ambitions.
Generics Bulletin - March 25, 2026

Daiichi Sankyo Looks To Deploy ‘Smarter’ R&D Approach To ADCs
As a pioneer in antibody-drug conjugates, Daiichi Sankyo has seen both breakthroughs and setbacks in advancing the modality. CEO Ken Keller told In Vivo the company had turned to next generation biomarker technologies to navigate these challenges and sharpen its R&D strategy.
In Vivo - March 25, 2026

Could CAR-T Cells Cure Some Autoimmune Diseases?
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
In Vivo - March 25, 2026

The Commercial Test: Psychedelics Move From Fringe Science To Doctor’s Office
Compass Pathways, now leading the race toward regulatory approval for a classic psychedelic, mapped out its strategy behind what could become one of the industry’s more unconventional drug launches.
In Vivo - March 25, 2026